Alatrofloxacin

CHEMBL1201197 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
558.5 g/mol
LogP
-0.2
Phase
4

A prodrug fluoroquinolone antibiotic that is converted in the body to trovafloxacin, a broad-spectrum antibacterial agent effective against a wide range of bacterial infections. It works by inhibiting bacterial DNA replication enzymes, preventing bacteria from reproducing and allowing the immune system to clear the infection.

Khối lượng phân tử

558,5000 g/mol

LogP

-0,20

TPSA

158,00 Ų

Lipinski RO5

Không đạt

Cơ chế tác dụng

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21

InChI

InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1

Molecular Formula

C26H25F3N6O5

HBD / HBA

4 / 12

Liên kết có thể quay

7

Nguyên tử nặng

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A prodrug fluoroquinolone antibiotic that is converted in the body to trovafloxacin, a broad-spectrum antibacterial agent effective against a wide range of bacterial infections. It works by inhibiting bacterial DNA replication enzymes, preventing bacteria from reproducing and allowing the immune system to clear the infection.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Alatrofloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201197. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3086677. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.